[425] Semler Scientific, Inc. Business Combination Communication
Strive, Inc. filed a communication under Rule 425 regarding its proposed business combination with Semler Scientific (SMLR). The message, reposted on X.com by a Strive board member, includes a forward‑looking statements caution.
Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, and an Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek their approval. Related documents will be available on the SEC’s website and company investor sites. The notice also identifies potential “participants in the solicitation” and states this is not an offer or solicitation to sell securities.
Strive, Inc. ha presentato una comunicazione ai sensi della Rule 425 riguardo alla sua proposta di fusione con Semler Scientific (SMLR). Il messaggio, ripubblicato su X.com da un membro del consiglio di Strive, include una cautela riguardo le dichiarazioni previsionali.
Strive intende presentare un Form S-4 per registrare le azioni ordinarie di Classe A da emettere nella transazione, e un Information Statement/Proxy Statement/Prospectus sarà inviato agli azionisti di Semler per ottenere la loro approvazione. I documenti correlati saranno disponibili sul sito della SEC e sui siti degli investitori dell'azienda. L'avviso identifica anche potenziali «partecipanti alla sollecitazione» e afferma che questa non è un'offerta o sollecitazione di vendere titoli.
Strive, Inc. presentó una comunicación bajo la Regla 425 respecto a su propuesta de combinación empresarial con Semler Scientific (SMLR). El mensaje, republicado en X.com por un miembro de la junta de Strive, incluye una advertencia sobre declaraciones prospectivas.
Strive tiene la intención de presentar un Form S-4 para registrar las acciones comunes de Clase A que se emitirán en la transacción, y se enviará a los accionistas de Semler un Information Statement/Proxy Statement/Prospectus para obtener su aprobación. Los documentos relacionados estarán disponibles en el sitio web de la SEC y en los sitios de inversores de la empresa. El aviso también identifica a posibles “participantes en la sol·licitación” y afirma que esto no es una oferta o solicitud de vender valores.
Strive, Inc.는 Semler Scientific (SMLR)와의 제안된 사업결합에 관해 Rule 425에 따라 소통을 제출했다. Strive 이사회 구성원에 의해 X.com에 재게시된 이 메시지는 전향적 진술에 대한 주의사항을 포함한다.
Strive는 거래에서 발행될 Class A 보통주를 등록하기 위해 Form S-4를 제출할 의도이며, 정보표/의결표/청약서(Prospectus)가 Semler 주주들에게 전달되어 승인받을 예정이다. 관련 문서는 SEC 웹사이트 및 회사 투자자 사이트에서 확인 가능하다. 또한 이 공지는 “solicitation 참가자” 가능성을 식별하고 이것이 주식의 판매를 위한 제안이나 청약이 아님을 명시한다.
Strive, Inc. a déposé une communication en vertu de la règle 425 concernant son projet de fusion avec Semler Scientific (SMLR). Le message, republié sur X.com par un membre du conseil de Strive, inclut une mise en garde sur les déclarations prospectives.
Strive a l'intention de déposer un Form S-4 pour enregistrer des actions ordinaires de Classe A qui seront émises dans la transaction, et une Information Statement/Proxy Statement/Prospectus sera envoyée aux actionnaires de Semler pour obtenir leur approbation. Les documents connexes seront disponibles sur le site Web de la SEC et sur les sites des investisseurs de l'entreprise. L'avis identifie également les potentiels « participants à la sollicitation » et indique qu'il ne s'agit pas d’une offre ou sollicitation de vendre des titres.
Strive, Inc. hat eine Mitteilung gemäß Regel 425 über die vorgeschlagene Unternehmenszusammenführung mit Semler Scientific (SMLR) eingereicht. Die Nachricht, von einem Strive-Vorstandsmitglied auf X.com erneut veröffentlicht, enthält einen Hinweis zu zukunftsgerichteten Aussagen.
Strive beabsichtigt, ein Form S-4 einzureichen, um im Rahmen der Transaktion auszugebende Class-A-Stammaktien zu registrieren, und ein Informations-/Proxy-/Prospectus wird an Semler-Aktionäre versandt, um ihre Zustimmung zu erhalten. Relevante Unterlagen werden auf der Website der SEC und auf den Investorenseiten des Unternehmens verfügbar sein. Die Mitteilung nennt außerdem potenzielle „Teilnehmer an der Solikitation“ und erklärt, dass dies kein Angebot oder keine Aufforderung zum Verkauf von Wertpapieren sei.
Strive, Inc. قدمت اتصالات بموجب القاعدة 425 بخصوص اندماجها المقترح مع Semler Scientific (SMLR). الرسالة، التي أعاد نشرها عضو مجلس إدارة Strive على X.com، تتضمن تحذيراً من التصريحات التطلعية.
تنوي Strive تقديم Form S-4 لتسجيل أسهم عادية من فئة A ستصدر في الصفقة، وسيتم إرسال بيان معلومات/بيان وكالة/نشرة الاكتتاب للمساهمين في Semler للحصول على موافقتهم. ستكون الوثائق ذات صلة متاحة على موقع SEC ومواقع المستثمرين الخاصة بالشركة. كما يحدد الإشعار أهداف “المشاركين في التحفيز/السعي” ويذكر أن هذا ليس عرضاً أو طلباً لبيع الأوراق المالية.
- None.
- None.
Insights
Strive signaled a proposed merger with Semler; S-4 and proxy/prospectus forthcoming. Material step, but no deal terms or timing disclosed.
This Rule 425 communication indicates a proposed business combination between Strive, Inc. and Semler Scientific, Inc. Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction. The S-4 will include an information statement of Strive, a proxy statement of Semler, and a prospectus of Strive, and Semler stockholders will be asked to approve. The communication was reposted on X on
The filing contains extensive forward-looking statements cautions, highlighting uncertainties around benefits, timing, and integration. It also clarifies that this is not an offer or solicitation. Until the S-4 is filed and a definitive proxy/prospectus is mailed, the transaction’s completion and terms remain subject to customary processes.
Watch for the S-4 filing and effectiveness, the definitive information/proxy/prospectus, and the Semler stockholder meeting date. Referenced materials include Strive’s current reports on
Strive, Inc. ha presentato una comunicazione ai sensi della Rule 425 riguardo alla sua proposta di fusione con Semler Scientific (SMLR). Il messaggio, ripubblicato su X.com da un membro del consiglio di Strive, include una cautela riguardo le dichiarazioni previsionali.
Strive intende presentare un Form S-4 per registrare le azioni ordinarie di Classe A da emettere nella transazione, e un Information Statement/Proxy Statement/Prospectus sarà inviato agli azionisti di Semler per ottenere la loro approvazione. I documenti correlati saranno disponibili sul sito della SEC e sui siti degli investitori dell'azienda. L'avviso identifica anche potenziali «partecipanti alla sollecitazione» e afferma che questa non è un'offerta o sollecitazione di vendere titoli.
Strive, Inc. presentó una comunicación bajo la Regla 425 respecto a su propuesta de combinación empresarial con Semler Scientific (SMLR). El mensaje, republicado en X.com por un miembro de la junta de Strive, incluye una advertencia sobre declaraciones prospectivas.
Strive tiene la intención de presentar un Form S-4 para registrar las acciones comunes de Clase A que se emitirán en la transacción, y se enviará a los accionistas de Semler un Information Statement/Proxy Statement/Prospectus para obtener su aprobación. Los documentos relacionados estarán disponibles en el sitio web de la SEC y en los sitios de inversores de la empresa. El aviso también identifica a posibles “participantes en la sol·licitación” y afirma que esto no es una oferta o solicitud de vender valores.
Strive, Inc.는 Semler Scientific (SMLR)와의 제안된 사업결합에 관해 Rule 425에 따라 소통을 제출했다. Strive 이사회 구성원에 의해 X.com에 재게시된 이 메시지는 전향적 진술에 대한 주의사항을 포함한다.
Strive는 거래에서 발행될 Class A 보통주를 등록하기 위해 Form S-4를 제출할 의도이며, 정보표/의결표/청약서(Prospectus)가 Semler 주주들에게 전달되어 승인받을 예정이다. 관련 문서는 SEC 웹사이트 및 회사 투자자 사이트에서 확인 가능하다. 또한 이 공지는 “solicitation 참가자” 가능성을 식별하고 이것이 주식의 판매를 위한 제안이나 청약이 아님을 명시한다.
Strive, Inc. a déposé une communication en vertu de la règle 425 concernant son projet de fusion avec Semler Scientific (SMLR). Le message, republié sur X.com par un membre du conseil de Strive, inclut une mise en garde sur les déclarations prospectives.
Strive a l'intention de déposer un Form S-4 pour enregistrer des actions ordinaires de Classe A qui seront émises dans la transaction, et une Information Statement/Proxy Statement/Prospectus sera envoyée aux actionnaires de Semler pour obtenir leur approbation. Les documents connexes seront disponibles sur le site Web de la SEC et sur les sites des investisseurs de l'entreprise. L'avis identifie également les potentiels « participants à la sollicitation » et indique qu'il ne s'agit pas d’une offre ou sollicitation de vendre des titres.
Strive, Inc. hat eine Mitteilung gemäß Regel 425 über die vorgeschlagene Unternehmenszusammenführung mit Semler Scientific (SMLR) eingereicht. Die Nachricht, von einem Strive-Vorstandsmitglied auf X.com erneut veröffentlicht, enthält einen Hinweis zu zukunftsgerichteten Aussagen.
Strive beabsichtigt, ein Form S-4 einzureichen, um im Rahmen der Transaktion auszugebende Class-A-Stammaktien zu registrieren, und ein Informations-/Proxy-/Prospectus wird an Semler-Aktionäre versandt, um ihre Zustimmung zu erhalten. Relevante Unterlagen werden auf der Website der SEC und auf den Investorenseiten des Unternehmens verfügbar sein. Die Mitteilung nennt außerdem potenzielle „Teilnehmer an der Solikitation“ und erklärt, dass dies kein Angebot oder keine Aufforderung zum Verkauf von Wertpapieren sei.
Strive, Inc. قدمت اتصالات بموجب القاعدة 425 بخصوص اندماجها المقترح مع Semler Scientific (SMLR). الرسالة، التي أعاد نشرها عضو مجلس إدارة Strive على X.com، تتضمن تحذيراً من التصريحات التطلعية.
تنوي Strive تقديم Form S-4 لتسجيل أسهم عادية من فئة A ستصدر في الصفقة، وسيتم إرسال بيان معلومات/بيان وكالة/نشرة الاكتتاب للمساهمين في Semler للحصول على موافقتهم. ستكون الوثائق ذات صلة متاحة على موقع SEC ومواقع المستثمرين الخاصة بالشركة. كما يحدد الإشعار أهداف “المشاركين في التحفيز/السعي” ويذكر أن هذا ليس عرضاً أو طلباً لبيع الأوراق المالية.
Strive, Inc. 已根据规则425就其与Semler Scientific (SMLR)的拟议商业结合提交通信。该信息由 Strive 董事会成员在 X.com 上转发，包含对前瞻性陈述的警告。
Strive 打算提交Form S-4以注册将在交易中发行的 Class A 普通股，并将向 Semler 股东发送信息声明/代理声明/招股说明书以寻求其批准。相关文件将在证券交易委员会网站和公司投资者网站上提供。通知还列出潜在的“招募参与者”，并声明这不是出售证券的要约或招募。
Filed by Strive, Inc.
(Commission File No.: 001-41612)
Pursuant to Rule 425 of the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Semler Scientific, Inc.
(Commission File No.: 001-36305)
The following communication was reposted on X.com by Pierre Rochard, Board Member of Strive, Inc. (“Strive”), on October 28, 2025, in connection with Strive’s proposed business combination with Semler Scientific, Inc. (“Semler Scientific”).
Cautionary Statement Regarding Forward-Looking Statements
Certain statements herein and the documents incorporated herein by reference may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Rule 175 promulgated thereunder, and Section 21E of the Exchange Act and Rule 3b-6 promulgated thereunder, which statements involve inherent risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements regarding the outlook and expectations of Strive and Semler Scientific, respectively, with respect to the proposed transaction, the strategic benefits and financial benefits of the proposed transaction, including the expected impact of the proposed transaction on the combined company's future financial performance, the timing of the closing of the proposed transaction, and the ability to successfully integrate the combined businesses. Such statements are often characterized by the use of qualified words (and their derivatives) such as "may," "will," "anticipate," "could," "should," "would," "believe," "contemplate," "expect," "estimate," "continue," "plan," "project," "predict," "potential," "assume," "forecast," "target," "budget," "outlook," "trend," "guidance," "objective," "goal," "strategy," "opportunity," and "intend," as well as words of similar meaning or other statements concerning opinions or judgment of Strive, Semler Scientific or their respective management about future events. Forward-looking statements are based on assumptions as of the time they are made and are subject to risks, uncertainties and other factors that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results expressed or implied by such forward-looking statements. Such risks, uncertainties and assumptions, include, among others, the following:
| · | the occurrence of any event, change or other circumstances that could give rise to the right of one or both of Strive and Semler Scientific to terminate the merger agreement between Strive and Semler Scientific; |
| · | the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not received or satisfied on a timely basis or at all; |
| · | the outcome of any legal proceedings that may be instituted against Strive or Semler Scientific or the combined company; |
| · | the possibility that the anticipated benefits of the proposed transaction, including anticipated cost savings and strategic gains, are not realized when expected or at all, including as a result of changes in, or problems arising from, implementation of Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets, general economic and market conditions, interest and exchange rates, monetary policy, and laws and regulations and their enforcement; |
| · | the possibility that the integration of the two companies may be more difficult, time-consuming or costly than expected; |
| · | the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events; |
| · | the diversion of management's attention from ongoing business operations and opportunities; |
| · | dilution caused by Strive's issuance of additional shares of its Class A common stock in connection with the proposed transaction; |
| · | potential adverse reactions of Strive’s or Semler Scientific’s customers or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed transaction; |
| · | changes in Strive’s or Semler Scientific’s share price before closing; |
| · | other factors that may affect future results of Strive, Semler Scientific or the combined company. |
These factors are not necessarily all of the factors that could cause Strive’s, Semler Scientific’s or the combined company's actual results, performance or achievements to differ materially from those expressed in or implied by any of the forward-looking statements. Other factors, including unknown or unpredictable factors, also could harm Strive, Semler Scientific or the combined company's results.
Although each of Strive and Semler Scientific believes that its expectations with respect to forward-looking statements are based upon reasonable assumptions within the bounds of its existing knowledge of its business and operations, there can be no assurance that actual results of Strive or Semler Scientific will not differ materially from any projected future results expressed or implied by such forward-looking statements. Additional factors that could cause results to differ materially from those described above can be found in Strive’s current report on Form 8-K filed with the Securities and Exchange Commission (the SEC) on September 12, 2025 (including the documents incorporated by reference therein), Semler Scientific’s most recent annual report on Form 10-K for the fiscal year ended December 31, 2024 and quarterly reports on Form 10-Q, and other documents subsequently filed by Strive and Semler Scientific with the SEC. The actual results anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on Strive, Semler Scientific or their respective businesses or operations. Investors are cautioned not to rely too heavily on any such forward-looking statements. Forward-looking statements speak only as of the date they are made and Strive and Semler Scientific undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.
2
Additional Information and Where to Find It
In connection with the proposed transaction, Strive intends to file with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the Class A common stock to be issued by Strive in connection with the proposed transaction and that will include an information statement of Strive, proxy statement of Semler Scientific and a prospectus of Strive (the "Information Statement/Proxy Statement/Prospectus"), and each of Strive and Semler Scientific may file with the SEC other relevant documents concerning the proposed transaction. A definitive Information Statement/Proxy Statement/Prospectus will be sent to the stockholders of Semler Scientific to seek their approval of the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF SEMLER SCIENTIFIC ARE URGED TO READ THE REGISTRATION STATEMENT AND INFORMATION STATEMENT/PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT STRIVE, SEMLER SCIENTIFIC AND THE PROPOSED TRANSACTION AND RELATED MATTERS.
A copy of the Registration Statement, Information Statement/Proxy Statement/Prospectus, as well as other filings containing information about Strive and Semler Scientific, may be obtained, free of charge, at the SEC's website (http://www.sec.gov). You will also be able to obtain these documents, when they are filed, free of charge, from Strive by accessing Strive's website at https://investors.strive.com/. Copies of the Registration Statement, the Information Statement/Proxy Statement/Prospectus and the filings with the SEC that will be incorporated by reference therein can also be obtained, without charge, by directing a request to Strive's Investor Relations department at 200 Crescent Court, Suite 1400, Dallas, Texas 75201 or by calling (855) 427-7360 or by submitting an inquiry at https://investors.strive.com/ir-resources/contact-ir. Copies of the documents filed with the SEC by Semler Scientific will be available free of charge on Semler Scientific’s website at https://ir.semlerscientific.com/. The information on Strive’s or Semler Scientific’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.
Participants in the Solicitation
Strive, Semler Scientific and certain of their respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Semler Scientific in connection with the proposed transaction. Information about the interests of the directors and executive officers of Strive and Semler Scientific and other persons who may be deemed to be participants in the solicitation of stockholders of Semler Scientific in connection with the proposed transaction and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the Information Statement/Proxy Statement/Prospectus related to the proposed transaction, which will be filed with the SEC. Information about the directors and executive officers of Semler Scientific, their ownership of Semler Scientific common stock, and Semler Scientific’s transactions with related persons is set forth in the section entitled "INFORMATION REGARDING OUR BOARD OF DIRECTORS AND CORPORATE GOVERNANCE," "EXECUTIVE OFFICERS," "SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT," “DIRECTOR COMPENSATION,” and "TRANSACTIONS WITH RELATED PERSONS" included in Semler Scientific’s definitive proxy statement in connection with its 2025 Annual Meeting of Stockholders, as filed with the SEC on July 17, 2025. Additional information regarding ownership of Semler Scientific’s securities by its directors and executive officers is included in such persons’ SEC filings on Forms 3 or 4, which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001554859. Information about the directors and executive officers of Strive is contained in Strive’s Current Report on Form 8-K filed with the SEC on September 15, 2025, Strive's Current Report on Form 8-K filed with the SEC on September 12, 2025 and under “Meet the Leadership Team” accessed through the “About Us” link on Strive’s website at https://strive.com/team. Additional information regarding ownership of Strive’s securities by its directors and executive officers is included in such persons’ SEC filings on Forms 3 or 4 which are available at https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=1920406. These documents and the other SEC filings described in this paragraph may be obtained free of charge as described above under the heading “Additional Information and Where to Find It.”
No Offer or Solicitation
This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or the solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements.
3
FAQ
What did Semler Scientific (SMLR) disclose in this update?
It shared a Rule 425 communication from Strive about a proposed business combination, including a forward‑looking statements caution and process details.
What filing will Strive submit for the SMLR transaction?
Strive intends to file a Form S-4 to register Class A common stock to be issued in connection with the proposed transaction.
Will Semler Scientific stockholders vote on the deal?
Yes. An Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek their approval.
Where can investors find the transaction documents?
Documents will be available on the SEC’s website and the investor relations sites of Strive and Semler Scientific.
Is this communication an offer to sell securities?
No. It expressly states it is not an offer or solicitation to sell or buy securities.
Who may be participants in the proxy solicitation for SMLR?
Strive, Semler Scientific, and certain directors, officers, and employees may be deemed participants, with details to be included in the proxy materials.
